Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927
Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million — — Company Reiterates 2026 Financial Expectations — DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026. “We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research. As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across multiple neuropsychiatric disorders and expect several important clinical data readouts over the year ahead. With a portfolio of development candidates in one of the most exciting new therapeutic categories in neuroscience and a steady cadence of clinical data readouts ahead, we believe we are well positioned to drive long-term value for shareholders.” Key Financial Highlights Revenues
Revenue Highlights Proprietary Product Revenues • VIVITROL revenues for the quarter were $127.6 million. During the quarter, the company recorded VIVITROL revenue of approximately $8 million related to gross-to-net favorability, primarily driven by favorable patient mix. 1 • ARISTADA i revenues for the quarter were $103.9 million, which included approximately $4 million of inventory benefit related to timing of shipments. During the quarter, the company recorded ARISTADA revenue of approximately $3 million related to gross-to-net favorability, primarily driven by favorable patient mix. • LYBALVI revenues for the quarter were $95.9 million, which included approximately $2 million of inventory benefit related to timing of shipments. Total prescriptions grew 18% compared to the third quarter of 2025. • LUMRYZ revenues for the quarter were $89.9 million. At the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy. Manufacturing & Royalty Revenues • VUMERITY ® manufacturing and royalty revenues for the quarter were $29.5 million. • Royalty revenue from XEPLION ® , INVEGA TRINZA ® /TREVICTA ® and INVEGA HAFYERA ® /BYANNLI ® for the quarter were $26.4 million. Key Operating Expenses
(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Avadel) employees which vested in full upon the closing of the transaction. Balance Sheet • At Sept. 30, 2026, the company recorded cash, cash equivalents and total investments of $787.6 million, compared to $691.6 million at June 30, 2026. Financial Expectations for 2026 Alkermes reiterates its financial expectations for 2026, as set forth in its press release dated July 28, 2026. Conference Call Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website. 2 About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a leadership position in orexin biology and is advancing a portfolio of investigational orexin 2 receptor agonists for narcolepsy, idiopathic hypersomnia and other psychiatric and neurological disorders, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense and non-recurring gains or losses in addition to the components of EBITDA from earnings.
The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non- GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company’s liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including expectations related to value creation; and expectations regarding development timelines for, and the potential therapeutic and commercial value of, the company’s orexin development candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not be able to achieve its financial expectations, including those related to value creation; clinical development activities may not be completed on time or at all; clinical study results may not be predictive of results from future stages of ongoing clinical studies, future clinical studies or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company’s products or products using the company’s proprietary technologies; the company’s products or product candidates may be shown to be ineffective or unsafe; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may not agree with the company’s regulatory approval strategies or components of its development programs, including clinical trial designs, conduct and methodologies, and may make adverse decisions regarding the company’s products; the company and its licensees may not be able to 3 continue to successfully commercialize their products or support revenue growth from such products; potential changes in the competitive landscape impacting our products, including earlier than anticipated entry of competition from generic forms of our products or competitive products and negotiated maximum fair pricing of competitive products; potential changes in the cost, scope and duration of the company’s development programs; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2025 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. VIVITROL ® is a registered trademark of Alkermes, Inc.; ARISTADA ® , ARISTADA INITIO ® and LYBALVI ® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; LUMRYZ ® is a registered trademark of Flamel Ireland Limited, an affiliate of Alkermes plc; BYANNLI ® , INVEGA HAFYERA ® , INVEGA TRINZA ® , TREVICTA ® and XEPLION ® , are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY ® is a registered trademark of Biogen MA Inc., used by Alkermes under license. (tables follow)
i The term “ARISTADA” as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.
Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP (In thousands, Three Months Three Months except per Ended Ended share data) September 30, September 30, Revenues: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Product sales, $ 417,280 $ 317,423 net Manufacturing and royalty 62,852 76,762 revenues Total Revenues 480,132 394,185 Expenses: Cost of goods manufactured 94,220 51,591 and sold Research and 121,120 81,739 development Selling, general and 208,502 171,773 administrative Amortization of acquired 19,698 — intangible assets Change in the fair value of 568 — contingent consideration Total Expenses 444,108 305,103 Operating 36,024 89,082 Income Other (Expense) Income, net: Interest 6,487 11,943 income Interest (27,551 ) — expense Other expense, (223 ) (280 ) net Total Other (Expense) (21,287 ) 11,663 Income, net Income Before 14,737 100,745 Income Taxes Income Tax (Benefit) (1,550 ) 17,984 Provision Net Income — $ 16,287 $ 82,761 GAAP Earnings Per $ 0.10 $ 0.50 Share - Basic Earnings Per Share - $ 0.09 $ 0.49 Diluted Weighted Average Number of Ordinary Shares Outstanding: Basic 167,872 165,086 Diluted 176,370 168,510 An itemized reconciliation between net income on a GAAP basis and Adjusted EBITDA is as follows: Net Income — $ 16,287 $ 82,761 GAAP Adjustments: Interest (6,487 ) (11,943 ) income Interest 27,551 — expense Income tax (benefit) (1,550 ) 17,984 provision Depreciation 7,461 8,060 expense Amortization of acquired 19,698 19 intangible assets EBITDA 62,960 96,881 Share-based 26,747 24,665 compensation Costs related to the 29,790 — acquisition of Avadel Change in the fair value of 568 — contingent consideration Adjusted $ 120,065 $ 121,546 EBITDA
Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP (In thousands, Nine Months Nine Months except per Ended Ended share data) September 30, September 30, Revenues: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Product $ 1,167,118 $ 869,151 sales, net Manufacturing and royalty 201,934 222,201 revenues Total 1,369,052 1,091,352 Revenues Expenses: Cost of goods manufactured 253,910 150,248 and sold Research and 337,385 230,926 development Selling, general and 690,720 514,326 administrati… Amortization of acquired 53,958 — intangible assets Change in the fair value of 26,982 — contingent consideration Total 1,362,955 895,500 Expenses Operating 6,097 195,852 Income Other (Expense) Income, net: Interest 20,370 33,174 income Interest (74,368 ) — expense Other (expense) (1,164 ) 2,047 income, net Total Other (Expense) (55,162 ) 35,221 Income, net (Loss) Income Before Income (49,065 ) 231,073 Taxes Income Tax 627 38,750 Provision Net (Loss) $ (49,692 ) $ 192,323 Income — GAAP (Loss) Earnings Per $ (0.30 ) $ 1.17 Share - Basic (Loss) Earnings Per $ (0.30 ) $ 1.14 Share - Diluted Weighted Average Number of Ordinary Shares Outstanding: Basic 167,037 164,490 Diluted 167,037 168,445 An itemized reconciliati… between net (loss) income on a GAAP basis and Adjusted EBITDA is as follows: Net (Loss) $ (49,692 ) $ 192,323 Income — GAAP Adjustments: Interest (20,370 ) (33,174 ) income Interest 74,368 — expense Income tax 627 38,750 provision Depreciation 22,907 23,262 expense Amortization of acquired 53,958 56 intangible assets EBITDA 81,798 221,217 Share-based 112,624 72,441 compensation Costs related to the acquisition 118,140 — of Avadel Change in the fair value of 26,982 — contingent consideration Adjusted $ 339,544 $ 293,658 EBITDA
Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Balance September 30, December 31, Sheets (In thousands) 2026 2025 Cash, cash equivalents and total $ 787,574 $ 588,360 investments Restricted cash — 731,206 Receivables 459,090 334,025 Inventory 261,098 196,625 Prepaid expenses and other current 105,086 79,090 assets Property, plant and 215,023 221,722 equipment, net Intangible assets, 1,741,758 815 net Goodwill 592,519 83,027 Deferred tax assets 120,771 125,815 Other assets 152,604 126,308 Total Assets $ 4,435,523 $ 2,486,993 Accrued sales discounts, allowances $ 323,406 $ 247,126 and reserves Long-term debt, 26,500 — current portion Other current 302,027 296,311 liabilities Long-term debt 1,471,231 — Other long-term 447,638 124,261 liabilities Total shareholders' 1,864,721 1,819,295 equity Total Liabilities and Shareholders' $ 4,435,523 $ 2,486,993 Equity Ordinary shares outstanding (in 168,030 165,607 thousands) This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which the company intends to file in November 2026.
Full text with the tables
Exhibit 99.1
Alkermes Contacts:
For Investors: Sandy Coombs +1 781 609 6377
For Media: Katie Joyce +1 781 249 8927
Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter
Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted
EBITDA of $120.1 Million — — Company Reiterates 2026 Financial Expectations —
DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial
results for the third quarter of 2026. “We delivered solid commercial and
financial performance in the third quarter while continuing to advance our
portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence
and other neuropsychiatric conditions,” said Blair Jackson, President and Chief
Executive Officer of Alkermes. “The rapid expansion of our orexin development
programs, highlighted by our recent clinical proof-of-concept data in ADHD and
initiation of a phase 2 study in major depressive disorder, further strengthens
our leadership position in orexin-based research. As we continue to advance our
orexin development portfolio, we are growing the body of evidence supporting the
potential of orexin biology across multiple neuropsychiatric disorders and
expect several important clinical data readouts over the year ahead. With a
portfolio of development candidates in one of the most exciting new therapeutic
categories in neuroscience and a steady cadence of clinical data readouts ahead,
we believe we are well positioned to drive long-term value for shareholders.”
Key Financial Highlights Revenues
Three Nine
Months Months
Ended Ended
(In September September
millions) 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Total $ 480.1 $ 394.2 $ 1,369.1 $ 1,091.4
Revenues
Total
Propriet… $ 417.3 $ 317.4 $ 1,167.1 $ 869.2
Net Sales
VIVITROL® $ 127.6 $ 121.1 $ 364.4 $ 343.8
ARISTADA… $ 103.9 $ 98.1 $ 294.4 $ 272.8
LYBALVI® $ 95.9 $ 98.2 $ 282.2 $ 252.6
LUMRYZ® $ 89.9 $ — $ 226.0 $ —
Profitability
Three
Months Nine Months
Ended Ended
(In September September
millions) 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP Net
Income $ 16.3 $ 82.8 $ -49.7 $ 192.3
(Loss)
EBITDA $ 63.0 $ 96.9 $ 81.8 $ 221.2
Adjusted $ 120.1 $ 121.5 $ 339.5 $ 293.7
EBITDA
Revenue Highlights Proprietary Product Revenues • VIVITROL revenues for the
quarter were $127.6 million. During the quarter, the company recorded VIVITROL
revenue of approximately $8 million related to gross-to-net favorability,
primarily driven by favorable patient mix.
1
• ARISTADA i revenues for the quarter were $103.9 million, which included
approximately $4 million of inventory benefit related to timing of shipments.
During the quarter, the company recorded ARISTADA revenue of approximately $3
million related to gross-to-net favorability, primarily driven by favorable
patient mix. • LYBALVI revenues for the quarter were $95.9 million, which
included approximately $2 million of inventory benefit related to timing of
shipments. Total prescriptions grew 18% compared to the third quarter of 2025. •
LUMRYZ revenues for the quarter were $89.9 million. At the end of the third
quarter, approximately 4,100 patients were on LUMRYZ therapy. Manufacturing &
Royalty Revenues • VUMERITY ® manufacturing and royalty revenues for the quarter
were $29.5 million. • Royalty revenue from XEPLION ® , INVEGA TRINZA ® /TREVICTA
® and INVEGA HAFYERA ® /BYANNLI ® for the quarter were $26.4 million. Key
Operating Expenses
Three
Months
Ended
September 2026
(In 30, Transac… 2025
millio… 2026GAAP Adjustm… 2026Non-… GAAP
──────────────────────────────────────────────────────────────────────────────
Cost of
Goods $ 94.2 $ 28.7 $ 65.6 $ 51.6
Sold
R&D $ 121.1 $ 0.1 $ 121.0 $ 81.7
Expense
SG&A $ 208.5 $ 1.0 $ 207.5 $ 171.8
Expense
Nine
Months
Ended
September 2026
(In 30, Transac… 2025
millio… 2026GAAP Adjustm… 2026Non-… GAAP
──────────────────────────────────────────────────────────────────────────────
Cost of
Goods $ 253.9 $ 72.4 $ 181.5 $ 150.2
Sold
R&D $ 337.4 $ 8.3 $ 329.1 $ 230.9
Expense
SG&A $ 690.7 $ 57.6 $ 633.1 $ 514.3
Expense
(1) Includes $20.2 million of share-based compensation expense related to the
acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc
(Avadel) employees which vested in full upon the closing of the transaction.
Balance Sheet • At Sept. 30, 2026, the company recorded cash, cash equivalents
and total investments of $787.6 million, compared to $691.6 million at June 30,
2026. Financial Expectations for 2026 Alkermes reiterates its financial
expectations for 2026, as set forth in its press release dated July 28, 2026.
Conference Call Alkermes will host a conference call and webcast presentation
with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3,
2026, to discuss these financial results and provide an update on the company.
The webcast may be accessed on the Investors section of Alkermes’ website at
www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988
for U.S. callers and +1 201 389 0923 for international callers. In addition, a
replay of the conference call may be accessed by visiting Alkermes’ website.
2
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global
biopharmaceutical company that seeks to develop innovative medicines in the
field of neuroscience. The company has a portfolio of proprietary commercial
products for the treatment of alcohol dependence, opioid dependence,
schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a
leadership position in orexin biology and is advancing a portfolio of
investigational orexin 2 receptor agonists for narcolepsy, idiopathic
hypersomnia and other psychiatric and neurological disorders, including
attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD)
and fatigue associated with multiple sclerosis and Parkinson’s disease.
Headquartered in Ireland, Alkermes also has a corporate office and research and
development center in Massachusetts and a manufacturing facility in Ohio. For
more information, please visit Alkermes’ website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that
are not prepared in accordance with generally accepted accounting principles in
the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures
are not based on any standardized methodology prescribed by GAAP and are not
necessarily comparable to similar measures presented by other companies.
EBITDA represents earnings before interest, tax, depreciation and amortization.
Adjusted EBITDA excludes share-based compensation expense and non-recurring
gains or losses in addition to the components of EBITDA from earnings.
The company’s management and board of directors utilize these non-GAAP financial
measures to evaluate the company’s performance. The company provides these non-
GAAP financial measures of the company’s performance to investors because
management believes that these non-GAAP financial measures, when viewed with the
company’s results under GAAP and the accompanying reconciliations, are useful in
identifying underlying trends in ongoing operations. However, EBITDA and
Adjusted EBITDA are not measures of financial performance under GAAP and,
accordingly, should not be considered as alternatives to GAAP measures as
indicators of operating performance. Further, EBITDA and Adjusted EBITDA should
not be considered measures of the company’s liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the
tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, including, but not limited to, statements concerning: the
company’s expectations concerning its future financial and operating
performance, business plans or prospects, including expectations related to
value creation; and expectations regarding development timelines for, and the
potential therapeutic and commercial value of, the company’s orexin development
candidates. The company cautions that forward-looking statements are inherently
uncertain. The forward-looking statements are neither promises nor guarantees
and they are necessarily subject to a high degree of uncertainty and risk.
Actual performance and results may differ materially from those expressed or
implied in the forward-looking statements due to various risks and
uncertainties. These risks and uncertainties include, among others: the company
may not be able to achieve its financial expectations, including those related
to value creation; clinical development activities may not be completed on time
or at all; clinical study results may not be predictive of results from future
stages of ongoing clinical studies, future clinical studies or real-world
results; the unfavorable outcome of arbitration, litigation, or other
proceedings or disputes related to the company’s products or products using the
company’s proprietary technologies; the company’s products or product candidates
may be shown to be ineffective or unsafe; the U.S. Food and Drug Administration
or regulatory authorities outside the U.S. may not agree with the company’s
regulatory approval strategies or components of its development programs,
including clinical trial designs, conduct and methodologies, and may make
adverse decisions regarding the company’s products; the company and its
licensees may not be able to
3
continue to successfully commercialize their products or support revenue growth
from such products; potential changes in the competitive landscape impacting our
products, including earlier than anticipated entry of competition from generic
forms of our products or competitive products and negotiated maximum fair
pricing of competitive products; potential changes in the cost, scope and
duration of the company’s development programs; there may be a reduction in
payment rate or reimbursement for the company’s products or an increase in the
company’s financial obligations to government payers; the company’s products may
prove difficult to manufacture, be precluded from commercialization by the
proprietary rights of third parties, or have unintended side effects, adverse
reactions or incidents of misuse; and those risks and uncertainties described
under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for
the year ended Dec. 31, 2025 and in subsequent filings made by the company with
the U.S. Securities and Exchange Commission (SEC), which are available on the
SEC’s website at www.sec.gov. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Except as required by law, the company disclaims any
intention or responsibility for updating or revising any forward-looking
statements contained in this press release. VIVITROL ® is a registered trademark
of Alkermes, Inc.; ARISTADA ® , ARISTADA INITIO ® and LYBALVI ® are registered
trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under
license; LUMRYZ ® is a registered trademark of Flamel Ireland Limited, an
affiliate of Alkermes plc; BYANNLI ® , INVEGA HAFYERA ® , INVEGA TRINZA ® ,
TREVICTA ® and XEPLION ® , are registered trademarks of Johnson & Johnson or its
affiliated companies; and VUMERITY ® is a registered trademark of Biogen MA
Inc., used by Alkermes under license. (tables follow)
i The term “ARISTADA” as used in this press release refers to ARISTADA and
ARISTADA INITIO®, unless the context indicates otherwise.
4
Alkermes plc
and
Subsidiaries
Selected
Financial
Information
(Unaudited)
Condensed
Consolidated
Statements of
Operations -
GAAP
(In thousands, Three Months Three Months
except per Ended Ended
share data) September 30, September 30,
Revenues: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Product sales, $ 417,280 $ 317,423
net
Manufacturing
and royalty 62,852 76,762
revenues
Total Revenues 480,132 394,185
Expenses:
Cost of goods
manufactured 94,220 51,591
and sold
Research and 121,120 81,739
development
Selling,
general and 208,502 171,773
administrative
Amortization
of acquired 19,698 —
intangible
assets
Change in the
fair value of 568 —
contingent
consideration
Total Expenses 444,108 305,103
Operating 36,024 89,082
Income
Other
(Expense)
Income, net:
Interest 6,487 11,943
income
Interest (27,551 ) —
expense
Other expense, (223 ) (280 )
net
Total Other
(Expense) (21,287 ) 11,663
Income, net
Income Before 14,737 100,745
Income Taxes
Income Tax
(Benefit) (1,550 ) 17,984
Provision
Net Income — $ 16,287 $ 82,761
GAAP
Earnings Per $ 0.10 $ 0.50
Share - Basic
Earnings Per
Share - $ 0.09 $ 0.49
Diluted
Weighted
Average Number
of Ordinary
Shares
Outstanding:
Basic 167,872 165,086
Diluted 176,370 168,510
An itemized
reconciliation
between net
income on a
GAAP basis and
Adjusted
EBITDA is as
follows:
Net Income — $ 16,287 $ 82,761
GAAP
Adjustments:
Interest (6,487 ) (11,943 )
income
Interest 27,551 —
expense
Income tax
(benefit) (1,550 ) 17,984
provision
Depreciation 7,461 8,060
expense
Amortization
of acquired 19,698 19
intangible
assets
EBITDA 62,960 96,881
Share-based 26,747 24,665
compensation
Costs related
to the 29,790 —
acquisition of
Avadel
Change in the
fair value of 568 —
contingent
consideration
Adjusted $ 120,065 $ 121,546
EBITDA
5
Alkermes plc
and
Subsidiaries
Selected
Financial
Information
(Unaudited)
Condensed
Consolidated
Statements of
Operations -
GAAP
(In
thousands, Nine Months Nine Months
except per Ended Ended
share data) September 30, September 30,
Revenues: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Product $ 1,167,118 $ 869,151
sales, net
Manufacturing
and royalty 201,934 222,201
revenues
Total 1,369,052 1,091,352
Revenues
Expenses:
Cost of goods
manufactured 253,910 150,248
and sold
Research and 337,385 230,926
development
Selling,
general and 690,720 514,326
administrati…
Amortization
of acquired 53,958 —
intangible
assets
Change in the
fair value of 26,982 —
contingent
consideration
Total 1,362,955 895,500
Expenses
Operating 6,097 195,852
Income
Other
(Expense)
Income, net:
Interest 20,370 33,174
income
Interest (74,368 ) —
expense
Other
(expense) (1,164 ) 2,047
income, net
Total Other
(Expense) (55,162 ) 35,221
Income, net
(Loss) Income
Before Income (49,065 ) 231,073
Taxes
Income Tax 627 38,750
Provision
Net (Loss) $ (49,692 ) $ 192,323
Income — GAAP
(Loss)
Earnings Per $ (0.30 ) $ 1.17
Share - Basic
(Loss)
Earnings Per $ (0.30 ) $ 1.14
Share -
Diluted
Weighted
Average
Number of
Ordinary
Shares
Outstanding:
Basic 167,037 164,490
Diluted 167,037 168,445
An itemized
reconciliati…
between net
(loss) income
on a GAAP
basis and
Adjusted
EBITDA is as
follows:
Net (Loss) $ (49,692 ) $ 192,323
Income — GAAP
Adjustments:
Interest (20,370 ) (33,174 )
income
Interest 74,368 —
expense
Income tax 627 38,750
provision
Depreciation 22,907 23,262
expense
Amortization
of acquired 53,958 56
intangible
assets
EBITDA 81,798 221,217
Share-based 112,624 72,441
compensation
Costs related
to the
acquisition 118,140 —
of
Avadel
Change in the
fair value of 26,982 —
contingent
consideration
Adjusted $ 339,544 $ 293,658
EBITDA
6
Alkermes plc and
Subsidiaries
Selected Financial
Information
(Unaudited)
Condensed
Consolidated Balance September 30, December 31,
Sheets
(In thousands) 2026 2025
Cash, cash
equivalents and total $ 787,574 $ 588,360
investments
Restricted cash — 731,206
Receivables 459,090 334,025
Inventory 261,098 196,625
Prepaid expenses and
other current 105,086 79,090
assets
Property, plant and 215,023 221,722
equipment, net
Intangible assets, 1,741,758 815
net
Goodwill 592,519 83,027
Deferred tax assets 120,771 125,815
Other assets 152,604 126,308
Total Assets $ 4,435,523 $ 2,486,993
Accrued sales
discounts, allowances $ 323,406 $ 247,126
and
reserves
Long-term debt, 26,500 —
current portion
Other current 302,027 296,311
liabilities
Long-term debt 1,471,231 —
Other long-term 447,638 124,261
liabilities
Total shareholders' 1,864,721 1,819,295
equity
Total Liabilities and
Shareholders' $ 4,435,523 $ 2,486,993
Equity
Ordinary shares
outstanding (in 168,030 165,607
thousands)
This selected
financial information
should be read in
conjunction with the
consolidated
financial statements
and
notes thereto
included in Alkermes
plc's
Quarterly Report on
Form 10-Q for the
quarter ended
September 30, 2026,
which
the company intends
to file in November
2026.
7
Alke…
plc
and
Subs…
Summ…
of
Costs
Rela… Three
to Months Net of
the Ended Costs Costs Three
Acqu… Septe… Relat… Relat… Months
of 30, to the to the Ended
Avad… 2026 Acqui… Acqui… Septe…
(In GAAP of of 30,
thou… Resul… Avadel Avadel 2025
──────────────────────────────────────────────────────────────────────────────
Cost
of
goods $ 94,220 $ 28,650 $ 65,570 $ 51,5…
manu…
and
sold
Rese…
and $ 121,1… $ 111 $ 121,0… $ 81,7…
deve…
Sell…
gene… $ 208,5… $ 1,029 $ 207,4… $ 171,…
and
admi…
Nine
Months
Ended
Septe…
30,
2026
Costs Net of Nine
Relat… Costs Months
(In GAAP to the Relat… Ended
thou… Resul… Acqui… to the Septe…
of Acqui… 30,
Avadel of 2025
(1) Avadel
Cost
of
goods $ 253,9… $ 72,413 $ 181,4… $ 150,…
manu…
and
sold
Rese…
and $ 337,3… $ 8,314 $ 329,0… $ 230,…
deve…
Sell…
gene… $ 690,7… $ 57,602 $ 633,1… $ 514,…
and
admi…
(1)
Incl…
$20,…
of
shar…
comp…
expe…
rela…
to
the
acce…
of
vest…
of
equi…
awar…
for
Avad…
empl…
which
vest…
in
full
upon
the
clos…
of
the
tran…
8